150TiP A phase Ib/II trial of a PD-1/VEGF bispecific antibody (PF-08634404) in combination with anticancer agents in first-line (1L) for advanced solid tumors (Symbiotic-Lung-20)
PF-08634404 is a fully human immunoglobulin G4 bispecific antibody that simultaneously targets PD-1 and VEGF. Phase II studies have shown promising efficacy and manageable safety with PF-08634404 as monotherapy and with chemotherapy in 1L non-small cell lung cancer (NSCLC). This study will evaluate PF-08634404 in combination with different anticancer agents in advanced solid tumors including NSCLC.
Authors
- Federico Cappuzzo (ORCID: https://orcid.org/0000-0002-6295-6767)
- Stefanie Gröpper (ORCID: https://orcid.org/0000-0002-2742-4941)
- Haiying Cheng (ORCID: https://orcid.org/0000-0002-6051-2732)
- Marium Siddiqui
- Eric Schaefer
- R. Martins
- T. Shimizu
- J. Kim
- K. Wakuda
- R. Tang
- S. Lu
- J. Zhao
- E. Felip
- Y. Lyou
- B. Wang
Institutions
- Kansai Medical University (JP)
- Montefiore Medical Center (US)
- Pfizer (United States) (US)
- Virginia Commonwealth University (US)
- Peking University (CN)
- Providence Portland Medical Center (US)
- Shanghai Chest Hospital (CN)
- Providence Hospital (US)
- Shizuoka Cancer Center (JP)
- Peking University Cancer Hospital (CN)
- Vall d'Hebron Hospital Universitari (ES)
- Marien Hospital Düsseldorf (DE)
- Tumori Foundation (US)
- Willamette Valley Cancer Institute and Research Center (US)
- Molecular Oncology (United States) (US)
- Rogers (United States) (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106457
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00